Developing novel blood-based biomarkers for Alzheimer's disease

Heather M Snyder¹, Maria C Carrillo², Francine Grodstein³, Kim Henriksen⁴, Andreas Jeromin⁵, Simon Lovestone⁶, Michelle M Mielke⁷, Sid O'Bryant⁸, Manual Sarasa⁹, Magnus Sjøgren¹⁰, Holly Soares¹¹, Jessica Teeling¹², Eugenia Trushina¹³, Malcolm Ward¹⁴, Tim West¹⁵, Lisa J Bain¹⁶, Diana W Shineman¹⁷, Michael Weiner¹⁸, Howard M Fillit¹⁷

Affiliations

¹ Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: hsnyder@alz.org.
² Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
³ Department of Medicine, Brigham and Women's Hospital, Inc., Boston, MA, USA.
⁴ Biomarker and Research Division, Nordic Biosciences, Copenhagen, Denmark.
⁵ NextGen Sciences Dx, Gainesville, FL, USA.
⁶ Institute of Psychiatry, Department of Medicine and Neurosciences, King's College, London, UK.
⁷ Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
⁸ Internal Medicine Department, University of North Texas Health Sciences Center at Fort Worth, Fort Worth, TX, USA.
⁹ Araclon Biotech, Zaragoza, Spain.
¹⁰ Diagenic ASA, Oslo, Norway.
¹¹ Bristol Myers Squibb, Co., Wallingford, CT, USA.
¹² University of Southampton, Southampton, UK.
¹³ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁴ Proteome Sciences plc, London, UK.
¹⁵ C2N Diagnostics, St Louis, MO, USA.
¹⁶ Independent Science Writer, Philadelphia, PA, USA.
¹⁷ Alzheimer's Drug Discovery Foundation, New York, NY, USA.
¹⁸ School of Medicine, University of California-San Francisco, San Francisco, CA, USA; Department of Veterans Affairs Medical Center, San Francisco, CA, USA.

PMID: 24365657
PMCID: PMC4769619
DOI: 10.1016/j.jalz.2013.10.007

Review

Developing novel blood-based biomarkers for Alzheimer's disease

Heather M Snyder et al. Alzheimers Dement. 2014 Jan.

. 2014 Jan;10(1):109-14.

doi: 10.1016/j.jalz.2013.10.007.

Authors

Affiliations

¹ Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA. Electronic address: hsnyder@alz.org.
² Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
³ Department of Medicine, Brigham and Women's Hospital, Inc., Boston, MA, USA.
⁴ Biomarker and Research Division, Nordic Biosciences, Copenhagen, Denmark.
⁵ NextGen Sciences Dx, Gainesville, FL, USA.
⁶ Institute of Psychiatry, Department of Medicine and Neurosciences, King's College, London, UK.
⁷ Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
⁸ Internal Medicine Department, University of North Texas Health Sciences Center at Fort Worth, Fort Worth, TX, USA.
⁹ Araclon Biotech, Zaragoza, Spain.
¹⁰ Diagenic ASA, Oslo, Norway.
¹¹ Bristol Myers Squibb, Co., Wallingford, CT, USA.
¹² University of Southampton, Southampton, UK.
¹³ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁴ Proteome Sciences plc, London, UK.
¹⁵ C2N Diagnostics, St Louis, MO, USA.
¹⁶ Independent Science Writer, Philadelphia, PA, USA.
¹⁷ Alzheimer's Drug Discovery Foundation, New York, NY, USA.
¹⁸ School of Medicine, University of California-San Francisco, San Francisco, CA, USA; Department of Veterans Affairs Medical Center, San Francisco, CA, USA.

PMID: 24365657
PMCID: PMC4769619
DOI: 10.1016/j.jalz.2013.10.007

Abstract

Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

Keywords: Alzheimer's disease; Biomarker; Blood based biomarker; Diagnostics; Early detection; Early diagnosis.

PubMed Disclaimer

References

1. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216. - PMC - PubMed
1. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J Alzheimers Dis. 2012;30:323–336. - PubMed
1. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med. 2010;4:65–79. - PMC - PubMed
1. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol. 2012;69:824–831. - PMC - PubMed
1. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jr., Jagust W, Decarli C, Toga AW, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122:401–413. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Developing novel blood-based biomarkers for Alzheimer's disease

Affiliations

Developing novel blood-based biomarkers for Alzheimer's disease

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous